The Phase 1 study (NCT04674306), conducted at Cleveland Clinics Main Campus in partnership with Anixa Biosciences, Inc., included 35 patients across three cohorts: Launched in 2021, the trial enrolled 26 patients in Phase 1a, four in Phase 1b, and five in Phase 1c
Some of its ways may include healing properties, tissue regeneration, and angiogenesis
J., Aldaz, P., Caball-Mestres, A., Moncho-Amor, V., Otaegi-Ugartemendia, M., Carrasco-Garcia, E., Olias-Arjona, A., Lasheras-Otero, I., Santamaria, E., Bocanegra, A., Chocarro, L., Grier, A., Dzieciatkowska, M
Best for patients whose primary goal is injury repair, faster recovery, or reducing chronic pain and inflammation
10.1002/art.41312 66 LoeserR